STOCK TITAN

Sight Sciences, Inc. - SGHT STOCK NEWS

Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.

Sight Sciences, Inc. (SGHT) pioneers transformative ophthalmic devices for glaucoma and dry eye treatment, merging surgical precision with evidence-based therapeutic solutions. This page serves as the definitive source for SGHT-related news, offering stakeholders timely updates on advancements shaping eye care innovation.

Access press releases, clinical trial results, and regulatory milestones covering minimally invasive glaucoma surgery (MIGS) technologies like the OMNI Surgical System and the TearCare System for dry eye management. Our curated collection ensures professionals and investors stay informed about product approvals, peer-reviewed research, and strategic partnerships driving the company’s growth.

Explore updates across key areas including surgical device innovations, real-world clinical data, and regulatory filings. Each announcement is vetted for relevance, providing actionable insights into SGHT’s market position and technological leadership in interventional eyecare.

Bookmark this page for streamlined access to Sight Sciences’ latest developments. Regularly updated with authoritative content, it empowers users to track progress in ophthalmic treatment solutions backed by clinical validation and engineering excellence.

Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) announced the initiation of the TRIDENT clinical trial to examine the OMNI Surgical System as a standalone treatment for lowering intraocular pressure (IOP) in glaucoma patients. This prospective, randomized trial is set to enroll 459 subjects across three study arms and aims to showcase the effectiveness of the next-generation OMNI device compared to the iStent inject. The trial marks a significant advancement in glaucoma management and aims to provide new evidence for treatment options tailored for patients post-cataract surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) appointed Brenda Becker to its Board of Directors on March 15, 2022. With over 40 years of experience in health policy and legislation, Becker will also serve on the Nominating and Governance Committee. Currently a Senior Vice President at Boston Scientific, her expertise is expected to aid the company in navigating regulatory challenges and enhancing access to innovative eyecare technologies. Becker previously held senior roles in the U.S. government, offering strategic insights crucial for the company's growth in ophthalmology and optometry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
management
-
Rhea-AI Summary

Sight Sciences, Inc. (Nasdaq: SGHT) will report its financial results for the quarter and year ended December 31, 2021, on March 24, 2022, after market close. A conference call to discuss the results will begin at 1:30 PM PT / 4:30 PM ET. The company's innovative solutions, such as the OMNI® and TearCare® systems, focus on improving patient care in eye diseases, including glaucoma and dry eye disease. Investors can access the conference call via webcast or by phone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
conferences earnings
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) announced that data from clinical studies of its OMNI® Surgical System will be presented at the 2022 American Glaucoma Society Annual Meeting in Nashville, TN, from March 3-6, 2022. Two posters are set for presentation, focusing on IOP fluctuation suppression and a retrospective analysis of 12-month outcomes in glaucoma treatments. The OMNI® system is a minimally invasive device aimed at reducing intraocular pressure in patients with primary open-angle glaucoma, enhancing treatment paradigms in eyecare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Citi Virtual Healthcare Conference scheduled for February 23, 2022, at 8:45 am PT. The management will engage in a fireside chat, accessible via a live and archived webcast on the company’s Investors section of its website. Sight Sciences focuses on transforming care standards through minimally invasive technologies, including the OMNI Surgical System for glaucoma and the TearCare System for dry eye treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) has launched the "Don't Wait for Too Late" educational campaign to promote minimally invasive glaucoma surgery (MIGS) as an early intervention for glaucoma. With glaucoma being a leading cause of irreversible blindness, early treatment is crucial. The use of MIGS, particularly the OMNI® Surgical System, offers new opportunities for patients with mild to moderate primary open-angle glaucoma (POAG), emphasizing reduced dependency on eye drops and better intraocular pressure management. The campaign aims to empower optometrists to recommend MIGS effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
none
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) announced preliminary financial results for Q4 and the full year 2021, forecasting total revenue between $14.5 million to $14.8 million for Q4, a 63% year-over-year increase, and full-year revenue between $48.8 million to $49.1 million, up 77%. Surgical Glaucoma revenues for Q4 are projected at $13.8 million to $14.0 million, while Dry Eye revenues are estimated at $0.7 million to $0.8 million. The company also highlighted significant accomplishments, including FDA clearances and advancements in clinical trials, with full results expected in March.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) has received FDA 510(k) clearance for its TearCare® System to treat meibomian gland dysfunction (MGD), a leading cause of dry eye disease. This clearance allows for localized heat therapy combined with manual gland expression in adult patients with evaporative dry eye. The OLYMPIA study demonstrated significant improvements in tear film stability and symptoms post-treatment. Sight Sciences aims to expand insurance coverage for this treatment to increase patient access, addressing a significant unmet need in the eyecare community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none
-
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) announced participation in the Piper Sandler Annual Virtual Healthcare Conference on November 22, 2021. The company focuses on innovative eyecare technology aimed at transforming care standards. Notable products include the OMNI® Surgical System, a minimally invasive glaucoma surgery device, and the TearCare® System, designed for treating evaporative dry eye disease. A recording of the fireside chat will be accessible on their investor website after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
conferences
Rhea-AI Summary

Sight Sciences (Nasdaq: SGHT) announced significant data from the 12-month GEMINI clinical trial showing that the OMNI Surgical System effectively reduces intraocular pressure (IOP) and stabilizes daily IOP fluctuations in patients with open-angle glaucoma. The study included 149 patients, demonstrating that 95% achieved lower peak IOP post-surgery, with a 36% decrease in variability compared to preoperative levels. The results support the device’s potential to improve patient outcomes in glaucoma treatments, encouraging future regulatory developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
Sight Sciences, Inc.

Nasdaq:SGHT

SGHT Rankings

SGHT Stock Data

136.54M
40.43M
20.6%
54.74%
3.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK